MediPharm Labs Sets Date to Report Second Quarter 2024 Financial Results
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), a pharmaceutical company specializing in precision-based cannabinoids, has announced the release date for its second quarter 2024 financial results. The results for the period ended June 30, 2024, will be released before markets open on Wednesday, August 14, 2024. Following the release, the company's executive management team will host a conference call and audio webcast at 8:30 a.m. (Eastern time) to discuss the financial results. Interested parties can join the call via a North America Toll-Free number or an International Toll number. An audio webcast will also be available, with a replay accessible on the company's website for those unable to participate live.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), un azienda farmaceutica specializzata in cannabinoidi di precisione, ha annunciato la data di pubblicazione dei suoi risultati finanziari del secondo trimestre 2024. I risultati per il periodo terminato il 30 giugno 2024, saranno pubblicati prima dell'apertura dei mercati mercoledì 14 agosto 2024. Dopo la pubblicazione, il team di gestione esecutiva dell'azienda ospiterà una chiamata in conferenza e un webcast audio alle 8:30 del mattino (ora orientale) per discutere i risultati finanziari. Le parti interessate possono partecipare alla chiamata tramite un numero verde per il Nord America o un numero internazionale. Sarà inoltre disponibile un webcast audio, con una registrazione accessibile sul sito web dell'azienda per coloro che non possono partecipare in diretta.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), una compañía farmacéutica especializada en cannabinoides de precisión, ha anunciado la fecha de publicación de sus resultados financieros del segundo trimestre de 2024. Los resultados del periodo que finaliza el 30 de junio de 2024, se publicarán antes de la apertura de los mercados el miércoles 14 de agosto de 2024. Después de la publicación, el equipo de gestión ejecutiva de la compañía llevará a cabo una llamada de conferencia y un webcast de audio a las 8:30 a.m. (hora del Este) para discutir los resultados financieros. Las partes interesadas pueden unirse a la llamada a través de un número gratuito de América del Norte o un número internacional. También habrá un webcast de audio disponible, con una repetición accesible en el sitio web de la empresa para aquellos que no puedan participar en vivo.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ)는 정밀 기반 대마유래 제품을 전문으로 하는 제약 회사입니다. 2024년 2분기 재무 결과 발표일을 발표했습니다. 2024년 6월 30일로 종료된 기간의 결과는 2024년 8월 14일 수요일, 시장 개장 전에 발표될 예정입니다. 발표 후, 회사의 경영진 팀은 동부 표준시 기준 오전 8시 30분에 재무 결과에 대해 논의하는 컨퍼런스 콜 및 오디오 웨비나를 진행할 예정입니다. 관심 있는 분들은 북미의 무료 전화번호나 국제 전화번호를 통해 콜에 참여할 수 있습니다. 또한 실시간 참여가 불가능한 분들을 위해 회사 웹사이트에서 재생 가능한 오디오 웨비나도 제공됩니다.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), une entreprise pharmaceutique spécialisée dans les cannabinoïdes de précision, a annoncé la date de publication de ses résultats financiers du deuxième trimestre 2024. Les résultats pour la période se terminant le 30 juin 2024 seront publiés avant l'ouverture des marchés le mercredi 14 août 2024. Après la publication, l'équipe de direction de l'entreprise animera une conférence téléphonique et un webcast audio à 8h30 (heure de l'Est) pour discuter des résultats financiers. Les parties intéressées peuvent joindre l'appel via un numéro gratuit pour l'Amérique du Nord ou un numéro international. Un webcast audio sera également disponible, avec une rediffusion accessible sur le site internet de l'entreprise pour ceux qui ne peuvent pas participer en direct.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), ein pharmazeutisches Unternehmen, das sich auf präzisionsbasierte Cannabinoide spezialisiert hat, hat das Veröffentlichungsdatum der finanziellen Ergebnisse für das zweite Quartal 2024 bekannt gegeben. Die Ergebnisse für den Zeitraum bis zum 30. Juni 2024 werden vor Markteröffnung am Mittwoch, den 14. August 2024 veröffentlicht. Nach der Veröffentlichung wird das Führungsteam des Unternehmens eine Konferenzschaltung und einen Audio-Webcast um 8:30 Uhr (Eastern Time) veranstalten, um die finanziellen Ergebnisse zu diskutieren. Interessierte Parteien können sich über eine gebührenfreie Nordamerikaleitung oder eine internationale Leitung in die Sitzung einwählen. Ein Audio-Webcast wird auch verfügbar sein, mit einer Wiedergabe, die auf der Unternehmenswebsite zugänglich ist, für diejenigen, die nicht live teilnehmen können.
- None.
- None.
MediPharm Labs executive management team will also host a conference call and audio webcast on Wednesday, August 14, 2024, at 8:30 a.m. (Eastern time) to discuss the Company's financial results.
Audio Conference Call Dial in Details:
North America Toll-Free: (888) 330-2454
International Toll: +1(240) 789-2714
Conference ID: 4921762
Participants are asked to dial in approximately 15 minutes before the start of the call.
Audio Webcast:
An audio webcast will be available by visiting the following link here.
For those who are unable to participate on the live conference call or webcast, a replay will be available at https://www.medipharmlabs.com/investors approximately one day after completion of the call.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in
In 2023, MediPharm acquired VIVO Cannabis Inc. which expanded MediPharm's reach to medical patients in
The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm's filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
View original content to download multimedia:https://www.prnewswire.com/news-releases/medipharm-labs-sets-date-to-report-second-quarter-2024-financial-results-302218257.html
SOURCE MediPharm Labs Corp.
FAQ
When will MediPharm Labs (MEDIF) release its Q2 2024 financial results?
What is the date and time of MediPharm Labs' (MEDIF) Q2 2024 earnings call?
How can investors access MediPharm Labs' (MEDIF) Q2 2024 earnings call?
Where can I find a replay of MediPharm Labs' (MEDIF) Q2 2024 earnings call?
